NCT02039687 — Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
ClinicalTrials.gov registry summary, not a standalone efficacy publication.
NCT02039687: COMPLETED; 64 participants (actual). This completed 64-participant randomized phase 2 trial has registry results posted. The published corneal nerve-fiber surrogate signal must be distinguished from the nonsignificant reported placebo-corrected pain comparison.
Registered clinical trial
Official ClinicalTrials.gov record.
- •Registry identifier: NCT02039687
- •Status: COMPLETED
- •Phase: PHASE2
- •Conditions: Neuropathy of Sarcoidosis
- •Enrollment: 64 (ACTUAL)
- •Allocation: RANDOMIZED
- •Results posted: Yes
- •Registry last updated: 2017-04-18
- •Record checked: October 15, 2026
Interpretation and limitations
This completed 64-participant randomized phase 2 trial has registry results posted. The published corneal nerve-fiber surrogate signal must be distinguished from the nonsignificant reported placebo-corrected pain comparison.
Read the related publication summary.
Registration records describe trial plans and administrative status. Completion alone does not establish efficacy; missing results do not prove treatment failure. The Educational evidence badge distinguishes these records from peer-reviewed human outcome studies. This is a dated registry snapshot, not live monitoring.
Connected compound
ARA-290 / cibinetide monograph. Research education only, not treatment advice.
Keywords
Research Goals
(1)For research use only. Not medical advice.